Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Inventory (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Inventory for 6 consecutive years, with $51.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Inventory changed N/A year-over-year to $51.6 million, compared with a TTM value of $51.6 million through Sep 2025, changed N/A, and an annual FY2024 reading of $43.9 million, down 27.9% over the prior year.
  • Inventory was $51.6 million for Q3 2025 at Cytek Biosciences, up from $49.5 million in the prior quarter.
  • Across five years, Inventory topped out at $66.9 million in Q3 2023 and bottomed at $32.2 million in Q4 2021.
  • Average Inventory over 5 years is $49.8 million, with a median of $49.4 million recorded in 2022.
  • The sharpest move saw Inventory soared 49.68% in 2022, then fell 27.9% in 2024.
  • Year by year, Inventory stood at $32.2 million in 2021, then skyrocketed by 49.68% to $48.2 million in 2022, then rose by 26.42% to $60.9 million in 2023, then dropped by 27.9% to $43.9 million in 2024, then grew by 17.67% to $51.6 million in 2025.
  • Business Quant data shows Inventory for CTKB at $51.6 million in Q3 2025, $49.5 million in Q2 2025, and $43.9 million in Q4 2024.